BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220711
DTEND;VALUE=DATE:20220714
DTSTAMP:20260516T024008
CREATED:20220330T093536Z
LAST-MODIFIED:20220623T094708Z
UID:33675-1657497600-1657756799@www.pharmajournalist.com
SUMMARY:3rd Annual Gene Therapy for Neurological Disorders Europe
DESCRIPTION:Accelerating Europe’s Progress in CNS Gene Therapy \nNavigating Europe-Specific Challenges & European Regulators Requirements; Optimizing Preclinical Research in Neurological Models & Revolutionizing Gene Therapy Delivery to CNS Targets in the Clinic \nAs programs advance globally\, the 3rd Annual Gene Therapy for Neurological Disorders Europe meeting is the industry’s definitive forum dedicated to showcasing the European landscape’s progress and specific regulatory challenges as they move from rare neurological disorders to targeting more common diseases including Parkinson’s\, epilepsy and neurodevelopmental disorders. \nReturning as its first in-person meeting\, with brand new speakers and companies joining the conversation\, attend alongside 100 fellow preclinical\, translational\, clinical and commercial gene therapy experts to overcome your translational challenges and improve the delivery of your gene therapy to its CNS target\, and optimize your European strategy as you move from rare to common patient populations. \nTo know more visit: https://ter.li/l4b1t3
URL:https://www.pharmajournalist.com/event/3rd-annual-gene-therapy-for-neurological-disorders-europe/
LOCATION:Paris Marriott Charles de Gaulle Airport Hotel\, Zone Hoteliere\, 5 All. du Verger\, Roissy-en-France\, 95700
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220711
DTEND;VALUE=DATE:20220714
DTSTAMP:20260516T024008
CREATED:20220412T094733Z
LAST-MODIFIED:20220412T094733Z
UID:33773-1657497600-1657756799@www.pharmajournalist.com
SUMMARY:Digital Biomarkers and Clinical Measures in Neurology Summit
DESCRIPTION:The Digital Biomarkers & Clinical Measures in Neurology Summit is the definitive industry forum sharing cross-industry insight to transform clinical development with digital data. \nFrom integrating wearable technologies\, smartphone apps\, and speech-based digital biomarkers into remote clinical research to elucidating pathways to clinical validation to establish therapeutic efficacy\, join industry experts from Merck\, Janssen\, GSK\, Sanofi\, Novartis\, Takeda\, Eli Lilly & Company\, Mitsubishi Tanabe Pharma Holdings America and many more to improve patient retention and establish efficacy with richer datasets. \nTo know more visit: https://ter.li/mk4lmh
URL:https://www.pharmajournalist.com/event/digital-biomarkers-and-clinical-measures-in-neurology-summit/
LOCATION:The Bostonian\, 26 North St\, Boston\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220712
DTEND;VALUE=DATE:20220715
DTSTAMP:20260516T024008
CREATED:20220413T082618Z
LAST-MODIFIED:20220413T085216Z
UID:33780-1657584000-1657843199@www.pharmajournalist.com
SUMMARY:3rd GxP Cloud Compliance Summit
DESCRIPTION:Migrate Your GxP Regulated Applications to the Cloud with Compliance\, Security\, & Quality Assurance  \nWith hot anticipation for the FDA’s new CSA guidance\, life science companies have the opportunity to take a proactive stance in their approach to the new methodologies. In the climate of this exciting new era of computer systems validation\, join over 100 Life Science\, IT & Quality professionals at the 3rd GxP Cloud Compliance Summit. \nEmulating on 2021’s success\, the 3rd GxP Cloud Compliance Summit is excited to return in July\, for the first time in person! \nThis is your only opportunity to develop and implement a practical roadmap to migrate your GxP regulated applications to the cloud with real-life insights from regulatory\, security and quality experts from leading life science companies\, as well as cloud providers\, auditors\, and industry regulators. \nWith the FDA strongly advising life science organizations to start getting ready for CSA now\, join us in July to discover how your business can get ahead and simplify the transition process. \nTo know more visit: https://ter.li/uichgz
URL:https://www.pharmajournalist.com/event/3rd-gxp-cloud-compliance-summit/
LOCATION:The Bostonian\, 26 North St\, Boston\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220712
DTEND;VALUE=DATE:20220715
DTSTAMP:20260516T024008
CREATED:20220427T072259Z
LAST-MODIFIED:20220427T072259Z
UID:33913-1657584000-1657843199@www.pharmajournalist.com
SUMMARY:BCMA Targeted Therapies Summit
DESCRIPTION:With the undeniable excitement in the BCMA field over the past few months\, the BCMA-Targeted Therapies Summit returns to the space to equip you with the knowledge and connections to revolutionize your BCMA-centered pipeline. \nPick the brains of 90+ academic and industry pioneers at the first physical edition of the only meeting dedicated to supercharging transformative next generation BCMA-targeted therapies into the clinic\, navigating the complex landscape and optimizing clinical strategy to revolutionize treatment of multiple myeloma and beyond. \nHear from leading speakers including: \n\n\n\nSuzette Girgis\, Senior Director & Head of Clinical Pharmacology & Hematologic Malignancies\, Johnson & Johnson Services\nEric Fedyk\, Global Program Leader of BCMA Assets\, 2seventy bio\nDavid DiLillo\, Director\, Immuno-Oncology\, Regeneron\nBrandon Kremer\, Group Senior Medical Director\, Clinical Development Lead\, GlaxoSmithKline\nNathan Martin\, Translational Scientist & Project Lead\, Bristol Myers Squibb\nMike Damore\, Director & Lead – Translational Oncology\, Pfizer\nChetasi Talati\, Medical Director\, AbbVie\nDexiu Bu\, Senior Principle Scientist\, CART group\, Immuno-Oncology & Hematology\, Novartis\nFaiza Zafar\, Senior Medical Science Liaison\, Legend Biotech\n\n\n\nTake a look at the full event guide to learn more.
URL:https://www.pharmajournalist.com/event/bcma-targeted-therapies-summit/
LOCATION:The Bostonian\, 26 North St\, Boston\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220713
DTEND;VALUE=DATE:20220715
DTSTAMP:20260516T024008
CREATED:20220323T103153Z
LAST-MODIFIED:20220324T101902Z
UID:33612-1657670400-1657843199@www.pharmajournalist.com
SUMMARY:Advanced Wound Care Summit
DESCRIPTION:The Advanced Wound Care Innovation Summit is the first industry-led forum focused on delivering innovative wound care treatments to patients. Expect to hear from\, and discuss with\, world leaders of wound care research who are driving the development of novel biomaterials\, remote-monitoring devices\, and digital health management solutions. \nFind out how C-level Executives\, VPs and Directors of R&D are tackling the most pressing industry challenges and seizing new growth opportunities. Whether an executive\, investor\, researcher or healthcare professional\, this meeting offers an empowering environment that allows you to make wound care decisions with confidence. \nTo know more visit: www.advancedwoundcareusa.com
URL:https://www.pharmajournalist.com/event/advanced-wound-care-summit/
LOCATION:Boston\, MA (Venue TBD)
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
END:VCALENDAR